Our Product Pipeline

Our DiversImmune™ and MultiMab™ platforms and licensing strategy have generated a pipeline of next-generation antibody product candidates, for which we have exclusive majority or full commercialization rights, as reflected in the following table:

Candidate Targets Indications Partner Abpro Commerical Rights Discovery Pre-Clinical IND-enabling Clinical
Immuno-Oncology
ABP-100 HER2/CD3 Breast, Gastric, Endometrial Worldwide

 

ABP-110 GPC3/CD3 Liver Worldwide

 

ABP-120 CD20/CD3 NHL
CLL
Worldwide

 

ABP-130 n.d./CD3 n.d. Worldwide (ex-China)

 

ABP-140 n.d./CD3 n.d. Worldwide (ex-China)

 

ABP-300 CD20/4-1BB NHL
CLL
Worldwide

 

ABP-500 FN14/CD47 Various liquid & solid tumors Worldwide

 

Ophthalmology
ABP-201* VEGF/ANG-2 DME
Wet AMD
Worldwide

 

Autoimmunity
ABP-400 SLAMF7 IgG4-RD Worldwide

 

* Held through our majority-owned subsidiary AbMed Corporation, or AbMed. MedImmune owns a minority stake in AbMed

Partners


MedImmune

MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across Oncology, Respiratory, Cardiovascular & Metabolic Diseases, and Infection and Vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centres, with additional sites in Cambridge, UK and Mountain View, CA. For more information, please visit www.medimmune.com.



Luye Pharma Group Ltd.

Luye Pharma Group Ltd. is a pharmaceutical company focused on research and development activities.The company was founded in 1994 and was listed on the main board of the Hong Kong Stock Exchange in 2014 (02186.HK). The company has state-of-the-art production facilities and R&D centers located in China, the USA and Europe, as well as overseas branch offices in Hong Kong, Singapore and Malaysia with approximately 4,000 employees.


Essex Bio

Essex Bio-Technology Limited is a pharmaceutical company which focuses on recombinant deoxyribonucleic acid (“DNA”) technology and specializes in research and development, manufacturing and sale of bio-pharmaceutical products for the healing of surface wounds, organ wounds and nervous system damage and disease.


Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center is a cancer treatment and research institution in New York City, founded in 1884 as the New York Cancer Hospital. Its main campus is located at 1275 York Avenue, between 67th and 68th Streets, in Manhattan.



Massachusetts General Hospital

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $850 million and major research centers in HIV/AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, genomic medicine, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, photomedicine and transplantation biology.